Year: 2025

Information on share capital and voting rights October 2025 Statement made in accordance with article L. 233-8 II of the French commercial Code and articles 221-1 2 ° f) and 223-16 of the AMF Regulations. November 3rd, 2025 Statement made by:         Nexans S.A.Registered office : 4 Allée de l’Arche – 92400 CourbevoieRCS Nanterre 393 525 852Regulated market of Euronext Paris (Compartment A)DateTotal number of sharesTotal number of voting rightsTheorical (1) Exercisable (2)October 31st, 2025 43,744,779 43,744,779 43,737,270(1)   Calculated based on all shares with voting rights, including treasury shares stripped of voting rights (Art. 223-11 of AMF General Regulations). (2)    For information, excluding treasury shares stripped of voting rights, excluding liquidity contract. Provision of Nexans articles of association...

Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Oslo, 3 November 2025: Zelluna ASA (“Zelluna” or the “Company”), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer contemplates a private placement of NOK 50-55 million in gross proceeds and a retail offering of new shares through PrimaryBid raising gross...

Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 results today. Webcast scheduled for 4 November 2025, at 09:00 (CET). Link to webcast here. Third Quarter 2025 Business Update HighlightsPositive MHRA feedback and strengthened clinical strategy supporting UK clinical developmentIn October 2025 (post period announcement), Zelluna announced it had received positive scientific advice from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). The feedback provided alignment across the preclinical, manufacturing, clinical, and regulatory strategy for ZI-MA4-1 and supports the planned Clinical Trial Application (CTA) submission later this year,...

PRESS RELEASE Wolters Kluwer shareholders approve appointment ofMs. Rose Lee and Mr. Hikmet Ersek to the Supervisory Board Alphen aan den Rijn, The Netherlands — November 3, 2025 — Wolters Kluwer announces that Ms. Rose Lee and Mr. Hikmet Ersek have been appointed as Members of the Supervisory Board by an Extraordinary General Meeting of Shareholders (“EGM”) held today. The appointments are effective immediately and are for the period starting November 3, 2025, and ending after the AGM to be held in 2030. Both candidates are seasoned executives with extensive managerial and Board experience in complex industries. Their appointment will further strengthen the Supervisory Board’s ability to oversee and support the company’s strategic direction aimed at long-term value creation. Ms. Lee is former CEO and Board member of Cornerstone Building...

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it is sponsoring the Dream Bowl 2026 and set a record date of November 14, 2025 for its shareholders to receive Dream Bowl 2026 Meme Coin, which will be distributed by DataVault AI. Scilex’s shareholders as of the record date of November 14, 2025 will receive one meme coin for each common share held. This digital collectible is intended to provide for immutable recognition of ownership and utility with ticketing information and embed exclusive details on invited athletes,...

Results exceed expectations Scottsdale, Ariz, Nov. 03, 2025 (GLOBE NEWSWIRE) — onsemi (the “Company”) (Nasdaq: ON) today announced its third quarter 2025 results with the following highlights:Revenue of $1,550.9 millionGAAP gross margin of 37.9% and non-GAAP gross margin of 38.0%GAAP operating margin of 17.0% and non-GAAP operating margin of 19.2%GAAP diluted earnings per share and non-GAAP diluted earnings per share of $0.63Cash from operations of $418.7 millionFree cash flow of $372.4 million grew 22% year-over-year to 24% of revenue Year-to-date share repurchases of $925 million, approximately 100% of free cash flow“Our third quarter results exceeded expectations, underscoring the strength of our strategy and the resilience of our business model. We’re seeing continued signs of stabilization across our core...

At 24 months, the target lesion primary patency (TLPP)1 was 41.7% At 24 months, the access circuit primary patency (ACPP)2 was 25.7%SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV. For the millions of patients diagnosed with advanced kidney disease, hemodialysis is a life-saving treatment that replaces the function of the kidneys. The administration of hemodialysis requires ongoing vascular access (access to blood vessels) that is commonly...

Aspocomp Group Plc, Stock Exchange Release, November 3, 2025 at 4:20 p.m. The new shares subscribed for in Aspocomp Group Plc’s directed share issue have been registered with the Trade Register. A total of 673,682 new shares subscribed for in Aspocomp’s Directed Share Issue have been registered with the Finnish Trade Register on October 31, 2025. After the registration of the new shares, the total number of shares in the company is 7,522,922 shares. The new shares will confer equal rights to the company’s existing shares from the date of registration. The new shares will be admitted to trading on Nasdaq Helsinki Ltd’s main list approximately from November 4, 2025 onwards. For further information, please contact Manu Skyttä, President and CEO,tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. ASPOCOMP GROUP PLC Manu SkyttäPresident and...

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent’s newest preclinical program; on-track for IND in 2026 WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced three presentations featuring bezuclastinib, including two oral presentations in NonAdvanced Systemic Mastocytosis (NonAdvSM), at the 67th Annual Meeting of the American Society of Hematology (ASH) being held December 6-9, 2025 in Orlando, FL. Cogent also announced today plans to describe its novel JAK2 V617F mutant-selective inhibitor as part of a poster presentation...